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Inflammatory Markers and Onset of Cardiovascular Events
Results From the Health ABC Study
Matteo Cesari, MD; Brenda W.J.H. Penninx, PhD; Anne B. Newman, MD, MPH;
Stephen B. Kritchevsky, PhD; Barbara J. Nicklas, PhD; Kim Sutton-Tyrrell, RN, DrPH;
Susan M. Rubin, MPH; Jingzhong Ding, PhD; Eleanor M. Simonsick, PhD;
Tamara B. Harris, MD, MS; Marco Pahor, MD
Background—Inflammation plays an important role in cardiovascular disease. The aim of this study is to investigate the
predictive value of several inflammatory markers on the incidence of cardiovascular events in well-functioning older
persons.
Methods and Results—The subjects were 2225 participants 70 to 79 years old, without baseline cardiovascular disease,
who were enrolled in the Health, Aging, and Body Composition study. Incident coronary heart disease (CHD), stroke,
and congestive heart failure (CHF) events were detected during an average follow-up of 3.6 years. Blood levels of
interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor- (TNF-) were assessed. After adjustment for
potential confounders, IL-6 was significantly associated with all outcomes (CHD events, per IL-6 SD increase: RR, 1.27;
95% CI, 1.10 to 1.48; stroke events, per IL-6 SD increase: RR, 1.45; 95% CI, 1.12 to 1.86; CHF events, per IL-6 SD
increase: RR, 1.72; 95% CI, 1.40 to 2.12). TNF- showed significant associations with CHD (per TNF- SD increase:
RR, 1.22; 95% CI, 1.04 to 1.43) and CHF (per TNF- SD increase: RR, 1.59; 95% CI, 1.30 to 1.95) events. CRP was
significantly associated with CHF events (per CRP SD increase: RR, 1.48; 95% CI, 1.23 to 1.78). A composite summary
indicator of inflammation showed a strong association with incident cardiovascular events, with an especially high risk
if all 3 inflammatory markers were in the highest tertile.
Conclusions—Findings suggest that inflammatory markers are independent predictors of cardiovascular events in older
persons. (Circulation. 2003;108:2317-2322.)
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Many cardiovascular events occur in persons withoutdocumented clinical or subclinical cardiovascular dis-
ease or known cardiovascular risk factors.1 Furthermore, the
predictive validity of traditional cardiovascular risk factors
diminishes with increasing age.2,3 Consequently, to better
identify patients at high risk for cardiovascular events, new
predictive markers need to be established, especially in aged
populations.
Various reports have indicated that inflammatory markers
appear to be predictive of cardiovascular events,4–11 but most
of these have focused on relatively young populations.5,7–10
Moreover, few articles have explored the predictive value of
inflammatory markers on cardiovascular events in cardiovas-
cular disease–free subjects,4,5,7,9,10,12,13 and even fewer have
considered multiple markers, such as interleukin-6 (IL-6),
C-reactive protein (CRP), and tumor necrosis factor- (TNF-
), simultaneously.4,14 In fact, most studies have focused only
on CRP.9–12,15–18 A recent longitudinal study among elderly
subjects without previous myocardial infarction has shown a
stronger role for IL-6 in the prediction of congestive heart
failure (CHF) than for CRP or TNF-.4
The aim of the present study was to assess the incidence of
coronary heart disease (CHD), stroke, and CHF events
according to serum levels of inflammatory markers (CRP,
IL-6, and TNF-) in a large sample of older, well-functioning
subjects.
Methods
Data are from the Health, Aging, and Body Composition (Health
ABC) study, a 7-year prospective cohort study designed to investi-
gate the impact of changes in body composition and health condi-
tions on age-related physiological and functional status. Participants,
70 to 79 years of age, were recruited between April 1997 and June
1998 from a list of Medicare beneficiaries residing in the areas
surrounding Pittsburgh, Pa, and Memphis, Tenn. Eligibility criteria
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included (1) no difficulty walking one quarter mile, climbing 10
steps, or performing basic activities of daily living; (2) no life-
threatening illness; and (3) no plans to leave the area for 3 years. In
all, 3075 persons were enrolled and completed baseline evaluation.
Participant had telephone contacts every 6 months and clinical visits
every year during which health status was assessed and data about
interim hospitalizations or major outpatient procedures were col-
lected. The presence of clinical disease at baseline was ascertained
by use of algorithms, mirroring adjudicated diagnoses in the Cardio-
vascular Health Study.19
The present study is based on 2225 participants; we excluded 34
participants because of missing data on all inflammatory markers and
816 participants with 1 of the following cardiovascular diseases at
baseline: CHF, CHD, stroke, or peripheral vascular disease, or
having a pacemaker. All participants gave informed consent; the
protocol was approved by the Institutional Review Boards of the
clinical sites.
Inflammatory Markers
Measures of levels of IL-6, TNF-, and CRP were obtained from
frozen stored serum (IL-6) or plasma (TNF-) collected by veni-
puncture after an overnight fast at baseline. Blood samples were
obtained in the morning, and after processing, the specimens were
divided into aliquots in cryovials, frozen at 70°C, and shipped to
the Health ABC Core Laboratory at the University of Vermont.
Cytokines were measured in duplicate by ELISA kit from R&D
Systems. The detectable limit for IL-6 (by HS600 Quantikine kit)
was 0.10 pg/mL and for TNF- (by HSTA50 kit) 0.18 pg/mL. Serum
levels of CRP were also measured in duplicate by ELISA on the
basis of purified protein and polyclonal anti-CRP antibodies (Cal-
biochem). The CRP assay was standardized according to World
Health Organization First International Reference Standard with a
sensitivity of 0.08 mg/L. The lower detection limit for CRP was
0.007 mg/L. Blind duplicate analyses (n150) for IL-6, CRP, and
TNF- showed interassay coefficients of variation of 10.3%, 8.0%,
and 15.8%, respectively.
Cardiovascular Events
Outcomes were as follows: incident CHD, defined by coronary death
or any overnight hospitalization in an acute care hospital for acute
myocardial infarction or angina; incident stroke, defined as fatal and
nonfatal stroke events; and incident CHF, defined as any overnight
hospitalization in an acute care hospital for CHF during the
follow-up.
Participants were questioned about any hospitalizations for CHD,
stroke, or CHF every 6 months. When an event was reported,
hospital records were collected and verified by a Health ABC
Disease Adjudicator at each site. Date and causes of death were
taken from the death certificate. Follow-up time was defined by the
time from the baseline visit until the first event date (for those who
had an event) or was censored at the last contact date (for those who
did not have any event or were lost to follow-up) or the day of death
(for those who died of noncardiovascular causes).
Covariates
Covariates included sociodemographic variables (age, gender, race,
study site, education), comorbidity (adjudicated presence of diabetes,
hypertension, chronic obstructive pulmonary disease [COPD], and
cancer), and physical and biological parameters, including smoking
status, body mass index (BMI, weight in kilograms divided by height
in meters squared), total cholesterol, HDL cholesterol, triglycerides,
creatinine, and albumin (all measured by a colorimetric technique on
a Johnson & Johnson Vitros 950 analyzer). LDL levels were
calculated by use of the Friedewald equation. Medications taken in
the previous 2 weeks were brought in, recorded, and coded according
to the Iowa Drug Information System. By use of this system,
nonsteroidal antiinflammatory drugs, systemic corticosteroids, an-
giotensin-converting enzyme inhibitors, and statins were identified.
Statistical Analyses
Differences in proportions and means of covariates across persons
with and without incident cardiovascular events during follow-up
were assessed by use of 2 and ANOVA statistics, respectively.
Because levels of inflammatory markers were not normally distrib-
uted, median values with interquartile ranges were reported, and
probability values were based on Mann-Whitney U statistics. To
assess the relative risk for incident cardiovascular events, Cox
proportional hazards analyses were performed; log-transformed val-
ues for inflammatory markers and tertile groups were used for these
analyses. To permit direct comparison between inflammatory mark-
ers, risks are shown per SD in log(inflammatory marker) increase.
Relative risks (RRs) and 95% CIs were adjusted for age, gender,
race, and all other covariates with a significant univariate association
with onset of cardiovascular events. Separate analyses were con-
ducted to evaluate relative risks for CHD, stroke, and CHF events.
Separate Cox proportional hazard analyses, adjusted for age,
gender, and race, were performed for inflammation and other
established cardiovascular risk factors (IL-6, CRP, and TNF- in
their highest tertile separately or together, current smoking, total
cholesterol 240 mg/dL, LDL cholesterol 130 mg/dL, HDL
cholesterol 40 mg/dL, hypertension, diabetes, obesity). Risks for
events were also calculated according to a composite summary
indicator of inflammation as the number of inflammatory markers in
the highest tertile.
Results
The 2225 participants (992 men [44.6%] and 1233 women
[55.4%]) had a mean age of 74.0 years (SD, 2.8 years) and
were more likely to be white (58.7%). The average follow-up
time was 3.6 years (SD, 0.9 years). During this period, 188
CHD events, 60 stroke events, and 92 CHF events were
reported. The incidence of cardiovascular events was signif-
icantly higher for those who smoked or had diabetes, hyper-
tension, COPD, high BMI, high levels of triglyceride and
creatinine, and low levels of HDL cholesterol and albumin
(Table 1).
CRP and IL-6 levels were correlated most strongly (Spear-
man r0.475, P0.001), but significant correlations were
also present between TNF- and IL-6 (r0.269, P0.001)
and between TNF- and CRP (r0.132, P0.001).
In univariate analyses (Table 2), participants with incident
CHD, stroke, and CHF events had higher levels of IL-6 at
baseline. TNF- levels were higher in those with CHD and
CHF events, whereas high CRP levels were found only for
those with CHF events.
Table 3 reports the predictive effect of levels of inflamma-
tory markers on cardiovascular events. The incidence of CHD
events was predicted by high levels of IL-6 (RR, 1.27; 95%
CI, 1.10 to 1.48) and TNF- (RR, 1.22; 95% CI, 1.04 to
1.43). IL-6 level was the only inflammatory marker that
significantly predicted stroke events (RR, 1.45; 95% CI, 1.12
to 1.86). The incidence of CHF events was predicted by high
levels of IL-6 (RR, 1.72; 95% CI, 1.40 to 2.12), CRP (RR,
1.48; 95% CI, 1.23 to 1.78), and TNF- (RR, 1.59; 95% CI,
1.30 to 1.95). No significant gender or race interaction was
found in the adjusted analyses for cardiovascular events.
Because albumin is considered a negative acute-phase reac-
tant, we reran analyses excluding it as a covariate to avoid an
overadjustment of our models, but results were very similar.
Separate proportional hazard models were fit for incident
CHD, stroke, and CHF events to compare inflammatory
markers and established cardiovascular risk factors (Table 4).
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For each outcome, inflammatory markers, especially IL-6,
were as potent or more potent predictors of disease onset
compared with traditional risk factors. Elevation of all 3
markers was the strongest predictor of both CHD and CHF
risk.
Restricted analyses in participants without traditional risk
factors (hypertension, diabetes, BMI 30 kg/m2, total cho-
lesterol240 mg/dL, HDL cholesterol40 mg/dL, and LDL
cholesterol 130 mg/dL) were performed to identify the
predictive value of inflammatory markers among persons
with a low cardiovascular risk profile. In this restricted
sample (17 events/307 participants; 5.5%), inflammatory
markers were still able to predict cardiovascular events (IL-6:
RR, 1.68; 95% CI, 1.11 to 2.55; CRP: RR, 1.34; 95% CI, 0.86
TABLE 1. Participants’ Characteristics
No Cardiovascular Events,
meanSD or %
(n1950)
Cardiovascular Events,
meanSD or %
(n275) P
Demographics
Age, y 74.02.8 74.33.0 0.12
Female gender 56.9 45.1 0.001
White race 58.5 60.4 0.55
Site, Memphis 51.1 50.9 0.95
Education 0.11
Less than high school 23.8 29.4
High school 33.8 32.7
Postsecondary 42.4 37.9
Smoking 0.001
Never 48.2 35.4
Former 42.0 52.2
Current 9.8 12.4
Baseline comorbid conditions
Diabetes 11.9 20.4 0.001
Hypertension 55.9 64.0 0.01
COPD 8.5 10.9 0.19
Cancer 18.9 16.0 0.25
Objective tests
BMI, kg/m2 27.34.9 28.05.1 0.03
Total cholesterol, mg/dL 205.037.8 203.437.5 0.52
HDL cholesterol, mg/dL 55.816.9 52.018.7 0.001
LDL cholesterol, mg/dL 122.934.5 122.734.5 0.92
Triglycerides, mg/dL* 116.0 (87.0–159.0) 123.0 (90.0–165.0) 0.04
Creatinine, mg/mL 1.00.4 1.10.4 0.07
Albumin, mg/mL 39.83.1 39.13.2 0.001
Medication use
Nonsteroidal antiinflammatory drugs 22.6 22.9 0.91
Angiotensin-converting enzyme inhibitors 12.2 12.4 0.94
Corticosteroids 2.0 2.9 0.33
Statins 9.0 10.2 0.52
*Expressed as median (25%–75%).
TABLE 2. Inflammatory Markers Levels (Median, Interquartile Range) According to Incident CHD, Stroke,
and CHF Events
No Events
(n1950)
CHD Events
(n188) P *
Stroke Events
(n60) P *
CHF Events
(n92) P *
IL-6, pg/mL 1.68 (1.16–2.54) 2.11 (1.40–3.13) 0.001 2.41 (1.78–3.17) 0.001 2.62 (1.62–4.35) 0.001
CRP, mg/L 1.61 (0.98–3.01) 1.74 (1.04–3.10) 0.193 1.99 (1.04–3.60) 0.102 2.70 (1.47–4.41) 0.001
TNF-, pg/mL 3.02 (2.35–3.86) 3.50 (2.67–4.66) 0.001 3.20 (2.38–4.42) 0.212 3.40 (2.67–5.33) 0.001
*P values vs No Events are based on Mann-Whitney U statistics.
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to 2.10; TNF-: RR, 1.36; 95% CI, 0.86 to 2.16), and the
relative risks were even somewhat higher then those found
among the 1918 participants with 1 cardiovascular risk
factors (258 events [13.5%]; IL-6: RR, 1.34; 95% CI, 1.18 to
1.52; CRP: RR, 1.20; 95% CI, 1.07 to 1.36; TNF-: RR, 1.22;
95% CI, 1.07 to 1.40).
Finally, we conducted analyses to examine the cardiovas-
cular risks according to a composite measure counting the
number of inflammatory markers in the highest tertile (Figure
1). The adjusted relative risk for cardiovascular events was
the highest when participants had the highest tertile level for
all 3 inflammatory markers. Participants with all 3 markers in
their highest tertile had a 2- to 3-fold increased risk for
CHD (1 marker: RR, 1.17; 95% CI, 0.79 to 1.73; 2 markers:
RR, 1.22; 95% CI, 0.79 to 1.88; 3 markers: RR, 2.13; 95% CI,
1.27 to 3.55) and CHF (1 marker: RR, 1.08; 95% CI, 0.56 to
2.08; 2 markers: RR, 1.97; 95% CI, 1.05 to 3.70; 3 markers:
RR, 4.85; 95% CI, 2.46 to 9.52) events compared with the
unexposed group. Similar but nonsignificant trends were
found for stroke events.
Discussion
The present study examined the predictive value of IL-6,
CRP, and TNF- for the incidence of CHD, stroke, and CHF
events in older adults without evidence of cardiovascular
disease at baseline. Our findings show that all 3 inflammatory
markers predicted the onset of cardiovascular events, and
individuals with high levels of all 3 markers had the greatest
risk of cardiovascular events. In our study, increased IL-6
level was the strongest and most consistent risk factor for
cardiovascular events.
In our study, IL-6 and TNF- showed more consistent
results than CRP in predicting cardiovascular events. Re-
cently, Vasan et al4 explored the predictive value of these
inflammatory markers on the onset of CHF in older subjects
without previous myocardial infarction. Their findings are
consistent with ours, showing a strong predictive value for the
all markers, particularly for IL-6. Similar findings were also
reported by Koukkunen et al,14 exploring the prognostic value
of these 3 inflammatory markers in older patients with CHD.
Perhaps, especially because of its wide range of actions,
including effects on platelets, endothelium, and factors of
metabolism and coagulation, IL-6 may have a more important
role in the development of CHD than some other inflamma-
tory markers.20
The association between inflammatory markers and stroke
has not been well studied. An inflammatory reaction is a
common response of the brain parenchyma to various forms
of insult. Cytokines play an important role during cerebral
ischemia21 and are involved in carotid atherosclerosis.12
Higher CRP levels have been shown to predict stroke.22 In
our study, we found an increased risk for stroke events in
participants with increased IL-6 levels but not for the other
inflammatory markers.
Our results confirm the strong relationship between inflam-
mation and CHF reported in previous studies. TNF- and
TABLE 3. Adjusted* RR (95% CI) for New CHD, Stroke, and CHF Events
According to Levels of Inflammatory Markers
CHD Events
(n188)
Stroke Events
(n60)
CHF Events
(n92)
IL-6, pg/mL
Per log(IL-6) increase 1.46 (1.16–1.84) 1.78 (1.20–2.65) 2.34 (1.70–3.24)
Per SD† in log(IL-6) increase 1.27 (1.10–1.48) 1.45 (1.12–1.86) 1.72 (1.40–2.12)
Tertile I‡: 0.21–1.34 (1.02) 1 1 1
Tertile II‡: 1.35–2.29 (1.73) 1.21 (0.81–1.80) 2.01 (0.86–4.67) 2.22 (1.02–4.84)
Tertile III‡: 2.30–15.96 (3.24) 1.61 (1.09–2.38) 3.70 (1.67–8.21) 5.08 (2.45–10.53)
CRP, mg/L
Per log(CRP) increase 1.13 (0.95–1.35) 1.22 (0.90–1.67) 1.60 (1.28–2.00)
Per SD† in log(CRP) increase 1.11 (0.96–1.29) 1.18 (0.91–1.53) 1.48 (1.23–1.78)
Tertile I‡: 0.15–1.15 (0.85) 1 1 1
Tertile II‡: 1.16–2.50 (1.65) 1.09 (0.76–1.57) 1.04 (0.53–2.03) 1.43 (0.77–2.65)
Tertile III‡: 2.51–85.18 (3.95) 1.20 (0.83–1.75) 1.41 (0.73–2.71) 2.60 (1.45–4.67)
TNF-, pg/mL
Per log(TNF-) increase 1.62 (1.10–2.38) 0.88 (0.44–1.76) 3.08 (1.88–5.05)
Per SD† in log(TNF-)
increase
1.22 (1.04–1.43) 0.95 (0.71–1.26) 1.59 (1.30–1.95)
Tertile I‡: 0.57–2.61 (2.07) 1 1 1
Tertile II‡: 2.62–3.61 (3.07) 1.45 (0.96–2.20) 0.99 (0.51–1.91) 1.67 (0.92–3.04)
Tertile III‡: 3.61–22.43 (4.42) 1.79 (1.18–2.71) 0.83 (0.41–1.66) 2.21 (1.24–3.96)
*Adjusted for age, gender, race, smoking, diabetes, hypertension, BMI, HDL cholesterol,
triglyceride, and albumin.
†SD for log(IL-6)0.64; SD for log(CRP)0.83; SD for log(TNF-)0.41.
‡Lower boundary–upper boundary (median).
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IL-6 levels are associated with the severity of left ventricular
dysfunction and with the degree of activation of the sympa-
thetic and renin-angiotensin systems.23 It has also been
reported that proinflammatory cytokines might depress myo-
cardial contractility.24 Over the past years, a series of multi-
center clinical trials using “targeted” approaches to neutralize
cytokines in patients with CHF have recently been conduct-
ed.25 Some of these trials failed to show substantial beneficial
effects of these new therapies for CHF.26 These results raise
important questions about the role that cytokines play in the
pathogenesis of CHF. Are higher levels of inflammatory
markers part of the pathophysiological pathway leading to
cardiovascular disease or just an indirect measure of subclin-
ical disease? If the latter is shown to be true, a treatment
aimed to lower inflammation might be useless.
Our results suggest that IL-6 and TNF- levels may be
stronger predictors for incident cardiovascular events than
CRP level. However, compared with most previous studies,
our sample included much older persons, in whom the
relationship between CRP and onset of cardiovascular events
may be weaker.27
We also provided a comparison between cardiovascular
risk factors, and high levels of inflammatory markers showed
the highest associations with incident cardiovascular event.
Some traditional cardiovascular risk factors failed to show a
significant relationship, confirming that the aging process
may diminish their reliability in the prediction of cardiovas-
cular events.5 In line with previous findings,7 our restricted
analyses on participants free from traditional cardiovascular
risk factors showed that IL-6 level was still able to predict the
new onset of cardiovascular disease. Cytokines may be
involved in the destabilization and disruption of the athero-
sclerotic plaque. In fact, the presence of inflammation char-
acterizes the site of plaque rupture,28 and proinflammatory
cytokines upregulate the expression of matrix metalloprotein-
ases, which are known to be involved in the vascular
remodeling and plaque disruption.29
The single blood sampling for cytokine dosage could be
influenced by the circadian rhythm they have and could be a
limitation of our study. This would tend to weaken the
observed associations because of added variability.
The recent AHA/CDC Scientific Statement30 about inflam-
matory markers and cardiovascular disease states that labo-
ratory tests assessing inflammation should be limited to those
that can be used in clinical settings, that have commercially
Adjusted relative risks for new CHD, stroke, and CHF events
according to number of inflammatory markers (IL-6, CRP, and
TNF-) in the highest tertiles (adjusted for age, gender, race,
smoking, diabetes, hypertension, COPD, BMI, HDL cholesterol,
triglyceride, creatinine, and albumin). n2225 participants. , No
cytokines highest tertiles (reference group); , highest tertile of 1
marker; ‘, highest tertiles of 2 markers; }, highest tertiles of 3
markers. Symbols indicate RR; lines indicate 95% CI. P for trend.
TABLE 4. Adjusted* RR (95% CI) for New CHD, Stroke, and CHF Events According to
Cardiovascular Risk Factors
CHD Events
(n188)
Stroke Events
(n60)
CHF Events
(n92)
IL-6 in highest tertile† 1.71 (1.27–2.29) 2.86 (1.71–4.80) 3.70 (2.39–5.75)
CRP in highest tertile† 1.33 (0.98–1.80) 1.64 (0.97–2.77) 2.40 (1.58–3.66)
TNF- in highest tertile† 1.67 (1.23–2.26) 1.18 (0.69–2.03) 1.90 (1.24–2.90)
Three inflammatory markers in highest tertile† 2.29 (1.49–3.53) 1.90 (0.86–4.21) 4.20 (2.53–6.97)
Current smoking 1.32 (0.98–1.77) 1.67 (0.98–2.82) 1.18 (0.77–1.81)
Total cholesterol 240 mg/dL 1.13 (0.76–1.70) 1.21 (0.62–2.36) 0.93 (0.52–1.66)
LDL cholesterol 130 mg/dL 1.07 (0.80–1.44) 1.32 (0.78–2.22) 0.72 (0.47–1.12)
HDL cholesterol 40 mg/dL 1.19 (0.84–1.70) 2.19 (1.20–3.99) 1.74 (1.05–2.90)
Hypertension 1.28 (0.95–1.22) 1.47 (0.86–2.51) 2.18 (1.36–3.49)
Diabetes 1.90 (1.33–2.70) 2.17 (1.18–4.01) 1.81 (1.08–3.02)
BMI 30 1.51 (1.10–2.07) 1.05 (0.58–1.91) 1.68 (1.08–2.61)
IL-6‡§ 1.36 (1.15–1.61) 1.53 (1.16–2.02) 1.52 (1.20–1.92)
CRP‡§ 1.01 (0.85–1.20) 1.08 (0.80–1.44) 1.26 (0.99–1.59)
TNF-‡§ 1.19 (1.02–1.39) 1.01 (0.77–1.33) 1.32 (1.07–1.63)
*Adjusted for age, gender, and race in separate proportional hazard models for each cardiovascular risk factor.
†Versus rest of the participants.
‡Per SD in log(unit) increase. SD for log(IL-6)0.64; SD for log(CRP)0.83; SD for log(TNF-)0.41.
§All 3 inflammatory markers are entered simultaneously in the proportional hazard model.
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available and standardized assays, and that present adequate
precision. It was suggested to limit current assays of inflam-
matory markers to CRP, using it as an adjunct to the major
traditional risk factors. Although our study finds a better
predictive value for IL-6 on the onset of cardiovascular
events, we agree that CRP still maintains its importance as a
marker of disease and, especially for its economic character-
istics, it is more suitable than others to be used right now.
However, this might change over time, when the assessment
of other cytokines will become more easily available and
cheaper and if our findings are confirmed by other studies.
Implementation of the assessment of inflammatory mark-
ers as additional risk factors to consider in addition to the
traditional ones in the evaluation of cardiovascular event risk
should be encouraged, especially in the elderly. Further
studies are needed to find out whether inflammatory markers
might represent valid targets for new medications able to
modify the atherosclerosis process.9,31
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